Fundz

Medi Wound Ltd reported raising $17.2 Million in an initial SEC Form D filing, from an offering of $17.2 Million

PUBLIC · MDWDOct 06, 2022

Amount Raised

$17.2 Million

$17.2 Million sold, per SEC Form D (first sale Sep 22, 2022)

Round Type

Venture

IsraelBiotechnologyHealthcareHealth CareTherapeutics

Quick answer

MediWound Ltd raised $17.2 Million in a funding round, dated September 22, 2022. MediWound Ltd is based in Israel.

How much did MediWound Ltd raise?
MediWound Ltd raised $17.2 Million in a funding round on September 22, 2022.
What does MediWound Ltd do?
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair.
Where is MediWound Ltd based and how big is it?
MediWound Ltd is based in Israel.
Who are the decision-makers at MediWound Ltd?
Fundz holds 1 contact at MediWound Ltd. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as MediWound Ltd that raised within 45 days of this round, from Fundz verified event records.

  • Biofrontera raised $3.7M (Seed) on October 25, 2022.
  • NewcelX raised $4M (Seed) on October 7, 2022.
  • Curavit Clinical Research raised $8.5M on September 28, 2022.
  • QurAlis raised $5M on August 12, 2022.
  • Novadip Biosciences raised $39M (Funding Round) on November 4, 2022.
  • Zenas BioPharma raised $184M on November 2, 2022.

Who to call at MediWound Ltd, and when

A new round usually means MediWound Ltd is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day MediWound Ltd raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at MediWound Ltd, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at MediWound Ltd. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

MediWound Ltd

Location

42 HAYARKON STREET

Israel

About

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment MediWound Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for MediWound Ltd's next move

See what Strategic adds

MediWound Ltd raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.